Transforming the Treatment of Neuropsychiatric Disorders
Approximately 21M people in the United States have MDD and 13M have PTSD. Up to one-third of adults are resistant to current available treatments. Transneural is focused on helping patients by developing novel neuroplastogens for neuropsychiatric conditions.
Enter your email below to receive updates on our progress
Focused pipeline, validated targets
Transneural is developing a pipeline of novel non-hallucinogenic neuroplastogens designed to deliver efficacy across a diverse range of neuropsychiatric indications
Seasoned industry approach to drug development
Transneural's leadership team has decades of experience developing and delivering blockbuster treatments to patients for depression, bipolar disorder, schizophrenia, and Alzheimer’s disease
Recognized drug discovery approach and platform
Transneural merges AI with traditional drug development to synthesize novel therapeutics with the potential to deliver better efficacy and safety to the millions of people sidelined by MDD, PTSD, and other neuropsychiatric disorders
Our Pipeline
Transneural’s pipeline of small molecules includes lead asset TN-001 and 3 additional programs
Unlocking the potential in today’s neuropsychiatric treatment renaissance
Our leadership team is comprised of scientific and strategic professionals at the forefront of CNS R&D. We have a proven track record identifying, developing, and commercializing blockbuster treatments.
Charmaine Lykins is a seasoned executive and recognized leader in neuropsychiatry with more than thirty years of pharmaceutical industry experience. Her career includes roles of increasing responsibility at Lundbeck, Sunovion, 15 years with Eli Lilly and Company, leading to C-suite level positions including Chief Commercial Officer of Karuna Therapeutics and MapLight Therapeutics, and Chief Marketing Officer of Acadia Pharmaceuticals. Ms. Lykins executed ten product launches throughout her career and served a pivotal role in driving the market success of multiple blockbuster products including KarXT/COBENFY®, NUPLAZID®, REXULTI®, ABILIFY MAINTENA® LATUDA®, ZYPREXA®, CYMBALTA®, and PROZAC®.
Mark A. Demitrack, MD is Chief Research and Development Officer of Transneural Therapeutics. He is an accomplished, internationally-recognized neuropsychiatrist with deep expertise in innovative clinical research and strategic business planning. Dr. Demitrack's over 30 years of industry experience includes Chief Medical Officer roles at Trevena and Neuronetics, where he led the clinical development program for the NeuroStar TMS Therapy System. Dr. Demitrack also served as Medical Director of the New Antidepressant Team at Lilly where he led the development and NDA submission for the antidepressant, duloxetine (Cymbalta). Dr. Demitrack was a faculty member of the Department of Psychiatry at the University of Michigan Medical School, where he received federal grant funding in clinical research investigations studying the neuroendocrine pathophysiology of mood and related disorders. Dr. Demitrack is a Fellow of the American Psychiatric Association and a Member of the American College of Neuropsychopharmacology. He has published over 100 articles, book chapters and reviews.
David Frawley has over twenty years of experience driving formidable growth for major pharmaceutical companies across therapeutic categories, including Psychiatry, Oncology, Neurology, and Respiratory. His solid, strategic leadership has consistently pioneered transformative growth initiatives and created motivated, aspirational cultures while delivering strong financial results at Karyopharm, Sunovion, Forest Laboratories, and Pfizer. Top products Mr. Frawley has commercialized include LATUDA®, VRAYLAR®, LEXAPRO®, and GEODON®. He has deep experience in M&A, licensing, managing global partnerships, and growing businesses in global markets while serving in leadership roles across the US, Canada, EMEA, and Europe.
Contact Us
